Pregabalin litigation - why did the SPCs lapse?

No items found.
​
31 May 2018
Tags
Life
Table of contents
  • Toc Heading
  • Toc Heading

Writing in the GRUR Newsletter ahead of the decision of the Supreme Court on the validity of a European patent owned by a subsidiary of Pfizer, covering the use of pregabalin in the treatment of pain, Darren Smyth looks at the various theories as to why the related SPCs were allowed to lapse.

Related articles

See all articles

EIP recognsied for strategic leadership in patent law at the Professional Services Management Excellence Awards
26 March 2026
EIP has been recognised with two Professional Services Management Excellence Awards 2026, including Excellence in Strategic Leadership and Best in Theme: Leadership. The awards reflect the firm’s commitment to aligning patent expertise with commercial insight, strengthening leadership across the firm and delivering patent strategy that supports investment, growth and high‑value business decisions.
​
EIP promotes Callum Docherty to Principal in the US
19 March 2026
EIP is pleased to announce the promotion of Callum Docherty to Principal, recognizing his substantial contribution to the firm’s international patent practice and his leadership within EIP’s growing US team.
​
EIP announces the promotion of Rob Barker to Partner
12 March 2026
EIP is pleased to announce the promotion of Robert Barker to Partner, recognising his significant contribution to the firm’s Digital, Chemistry, Life Sciences, and multidisciplinary patent practice since joining in 2014.
​